Earlier this week, new phase 2 data showed investigative therapy sotatercept was beneficial in improving pulmonary vascular resistance and six-minute walking test (6MWT) outcomes in patients with pulmonary arterial hypertension (PAH) at 24 weeks.
CU Anschutz
Fitzsimons Building
13001 East 17th Place
Aurora, CO 80045